(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 April 2008 (24.04.2008)

PCT

(10) International Publication Number
WO 2008/046757 A1

(51) International Patent Classification:
C07D 233/64 (2006.01) *A61P 25/00* (2006.01)
A61K 31/4178 (2006.01)

(21) International Application Number:
PCT/EP2007/060666

(22) International Filing Date: 9 October 2007 (09.10.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
06122586.8 19 October 2006 (19.10.2006) EP

(71) Applicant *(for all designated States except US)*: **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **GALLEY, Guido** [DE/DE]; Katzenbuckelweg 14, 79618 Rheinfelden (DE). **GOERGLER, Annick** [FR/FR]; 5, mittlerer Noehlen Pfad, F-68000 Colmar (FR). **GROEBKE ZBINDEN, Katrin** [CH/CH]; Laubibergstrasse 61, CH-4410 Liestal (CH). **NORCROSS, Roger** [GB/CH]; Maetteli 244, CH-4305 Olsberg (CH). **STALDER, Henri** [CH/CH]; Strassburgerallee 83, CH-4055 Basel (CH).


(74) Agent: **POPPE, Regina**; Grenzacherstrasse 124, CH-4070 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

(54) Title: AMINOMETHYL-4-IMIDAZOLES



(I)

(57) **Abstract:** The present invention relates to compounds of formula (I) wherein R^1 is hydrogen, lower alkyl, -$(CR_2)_n$-OH, -$(CH2)_n$-aryl or -$(CH_2)_n$-heteroaryl, which are optionally substituted by halogen, lower alkoxy or lower alkyl substituted by halogen, or is -$(CR_2)_n$- cycloalkyl, optionally substituted by hydroxy, -$(CH_2)_n$-heterocyclyl, -$(CH_2)_n$-NH-$S(O)_2CH_3$, or is -$(CR_2)_n$O-lower alkyl or lower alkyl substituted by halogen; R is hydrogen or lower alkyl, and when two R-groups are present, they may or may not be the same; R^2 is 2,2-dioxo-2,3-dihydro-1*H*-benzo[c]thiophenyl, 6,7-dihydro-5*H*-cyclopentapyrimidin-2-yl, 2,2-difluoro-benzo[1,3]dioxol-5-yl, 2,2,3,3-tetrafluoro-2,3-dihydro-benzo[1,4]dioxin-6-yl, or is aryl or heteroaryl, optionally substituted by one or more substituents, selected from the group consisting of halogen, lower alkyl, cycloalkyl, -$(CH_2)_n$-hydroxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, -$S(O)_2$-lower alkyl, -$(CH_2)_n$-$S(O)_2$-NH-lower alkyl, -$(CH_2)_n$-O-lower alkyl, nitro, amino, cyano, -NHC(O)-lower alkyl, -C(O)NH-lower alkyl, or O-tetrahydro-naphthalenyl, or are substituted by -$(CH_2)_n$-aryl, optionally substituted by halogen, or by -CH=CH-aryl, optionally substituted by halogen, or by -$(CH_2)_n$-O-aryl, optionally substituted by halogen, lower alkoxy or lower alkyl substituted by halogen, or by -O-$(CH_2)_n$-aryl, optionally substituted by halogen, or by -$(CH_2)_n$-heteroaryl, or by -$(CH_2)_n$-O-heteroaryl or by -$(CH_2)_n$-heterocyclyl, optionally substituted by =O, or by -$(CH_2)_n$-O-heterocyclyl, optionally substituted by lower alkyl, or by -S-aryl, -CH(OH)-aryl, -$C(CH_3)_2$-aryl, -NR-aryl, or by 2-oxo-2H-pyridin-1-yl; R^3 is hydrogen or lower alkyl; R^4 is hydrogen or lower alkyl; n is 0, 1, 2, 3 or 4 and to their pharmaceutically active salts for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

WO 2008/046757 A1